Look at Sun Pharma, says Gaurang Shah

Gaurang Shah of Geojit BNP Paribas told CNBC-TV18, "In Sun Pharmaceutical Industries we believe that the negativities in terms of Ranbaxy merger is a thing of the past. Contribution from Taro has been at a lower level. We believe there is scope of improvement. In terms of approvals where they have been able to get couple of approvals, in terms of resolution of their Halol plant, the sooner they do it, the better it is because this is one manufacturing facility, which adds to their export market in terms of topline and bottomline. We are having a positive coverage."Sun Pharmaceutical Industries ended at Rs 756, down Rs 8.85, or 1.16 percent on the BSE.